Every month, we track pricing across 15+ telehealth GLP-1 providers to give you an honest snapshot of what these programs actually cost. March 2026 brought some notable shifts — including one major price drop and one provider quietly raising rates.
The Cheapest Options Right Now
Here is where pricing stands as of March 27, 2026, ranked by lowest monthly cost for semaglutide-based programs:
1. bmiMD — Starting at $100/month bmiMD continues to hold the lowest entry price in the market. Their $100/month plan includes compounded semaglutide (while still legally available), provider consultations, and basic messaging support. The catch: this is for the lowest dose tier only. Maintenance doses run $150-200/month. Note that bmiMD uses compounded medications, which carry the regulatory risks we have covered extensively.
2. Willow — Starting at $149/month Willow offers FDA-approved semaglutide (Wegovy) starting at $149/month through their insurance navigation program. This price assumes your commercial insurance covers Wegovy and Willow handles the prior authorization. Without insurance coverage, their self-pay program starts at $299/month — still competitive for brand-name medication.
3. Ro — Starting at $199/month (brand-name only) Ro exclusively prescribes FDA-approved brand-name medications and does not offer compounded alternatives. Their $199/month starting price includes the medication cost with their savings card program, provider visits, and ongoing clinical support. This is the cheapest brand-name-only option without requiring insurance.
4. Eden Health — Starting at $225/month Eden Health provides the most comprehensive clinical program at this price point, including lab monitoring, nutrition coaching, and access to multiple medication options. They prescribe both brand-name and compounded GLP-1s depending on patient preference and clinical needs.
What Changed This Month
Price drop: Willow reduced their self-pay tier by $50. Willow's self-pay semaglutide program dropped from $349/month to $299/month — a significant reduction that makes them more competitive with brand-name-only providers. They attributed the change to improved manufacturer savings card programs.
Price increase: Henry Meds raised their base rate by $25. Henry Meds moved their starting semaglutide price from $249 to $274/month, citing "increased compliance and quality assurance costs." This puts them at the higher end of the mid-tier providers.
New entrant: Calibrate relaunched with revised pricing. After a rocky 2025 that included layoffs and program restructuring, Calibrate relaunched their metabolic health program at $199/month for members who bring their own GLP-1 prescription, plus a $249/month all-inclusive tier. The relaunched program emphasizes behavioral change and metabolic coaching alongside medication.
Compounded vs. Brand-Name: The Price Gap Is Narrowing
One of the most important trends we are tracking is the shrinking price gap between compounded and brand-name GLP-1 medications. Twelve months ago, compounded semaglutide typically cost $150-200/month while brand-name Wegovy ran $300-500/month through telehealth. Today, thanks to manufacturer savings programs, insurance expansion, and the upcoming Medicare Bridge, brand-name access at under $200/month is achievable for many patients.
This matters because the FDA's ongoing crackdown on compounders (12 more warning letters this month alone) means the compounded supply could become unreliable. Patients who are price-sensitive should explore brand-name options now rather than waiting until their compounded supply is disrupted.
Insurance Coverage Update
Commercial insurance coverage for GLP-1 weight loss medications continues to expand. UnitedHealthcare, the nation's largest insurer, confirmed in February that it would maintain GLP-1 coverage for obesity (BMI 30+) across all fully insured plans in 2026. Aetna, Cigna, and Blue Cross Blue Shield plans in most states also cover at least one GLP-1 for weight management.
If your employer plan does not cover GLP-1s, ask your HR department — many plans added coverage during 2025-2026 renewals without widely publicizing the change.
The Bottom Line
The GLP-1 market is becoming more affordable and more accessible every month. If cost has been your primary barrier, the current landscape offers options at nearly every budget level. Our recommendation: prioritize FDA-approved medications when you can afford them, and if you are on a compounded product, start exploring your transition options now.